- Subgroup Analysis by Ki-67 and Primary Tumor Origins of the Randomized, Placebo-Controlled Phase 3 Study of Surufatinib in Advanced Well-Differentiated Extrapancreatic Neuroendocrine Tumors (SANET-ep)Zhou, Zhiwei; Xu, Jianming; Shen, Lin; Li, Jie; Bai, Chunmei; Chi, Yihebali; Li, Zhiping; Xu, Nong; Li, Enxiao; Liu, Tianshu; Bai, Yuxian; Yuan, Ying; Li, Xingya; Wang, Xiuwen; Chen, Jia; Wang, Wei; Guan, Sha; Fan, Songhua; Su, Weiguo
- Health-Related Quality-of-Life Analysis of Surufatinib Versus Placebo for Advanced Neuroendocrine Tumors: Pooled Results From Two Phase 3 Studies (SANET-p and SANET-ep)Bai, Chunmei; Xu, Jianming; Shen, Lin; Li, Jie; Zhou, Zhiwei; Li, Zhiping; Chi, Yihebali; Yu, Xianjun; Li, Enxiao; Xu, Nong; Liu, Tianshu; Lou, Wenhui; Bai, Yuxian; Yuan, Xianglin; Wang, Xiuwen; Yuan, Ying; Chen, Jia; Guan, Sha; Fan, Songhua; Su, Weiguo
- A pooled analysis of surufatinib safety from phase 3 trials in advanced NETs.Li, Jie; Xu, Jianming; Shen, Lin; Bai, Chunmei; Zhou, Zhiwei; Li, Zhiping; Chi, Yihebali; Yu, Xianjun; Li, Enxiao; Xu, Nong; Liu, Tianshu; Lou, Wenhui; Bai, Yuxian; Yuan, Xianglin; Wang, Xiuwen; Yuan, Ying; Chen, Jia; Zhang, Tao; Xiu, Dianrong; Su, WeiguoAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 2022-06-03 To 2022-06-07.
会议论文
Subgroup Analysis by Ki-67 and Baseline CgA of the Randomized, Placebo-Controlled Phase 3 Study of Surufatinib in Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors (SANET-p)
23阅读
